

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Applicant:</b>	Paul J. Coleman, et al.	<b>Art Unit:</b>	To be determined
<b>Attorney Docket No.</b>	21358P	<b>Examiner:</b>	To be determined
<b>PCT Appl. No.:</b>	PCT/US04/018137		
	Filed: 8 June 2004		
<b>Filing Date:</b>	December 7, 2005		
<b>For:</b>	MITOTIC KINESIN INHIBITORS		

Mail Stop: PCT  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**LETTER**

Sir:


In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21358P.

EXPRESS MAIL CERTIFICATE  
DATE OF DEPOSIT Dec. 7, 2005  
EXPRESS MAIL NO. EV 421343112 US  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"  
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO  
COMMISSIONER FOR PATENTS, P.O. BOX 1450,  
ALEXANDRIA, VIRGINIA 22313-1450.  
MAILED BY Don Schepise  
DATE 12-7-05

Respectfully submitted,

By:   
David A. Muthard  
Registration No. 35,297  
Attorney for Applicants  
  
Merck & Co., Inc.  
P.O. Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-3903

Date: December 7, 2005